| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 24 | 2025 | 1359 | 3.720 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2026 | 729 | 3.560 |
Why?
|
| Cardiovascular Diseases | 20 | 2025 | 862 | 3.280 |
Why?
|
| Myocarditis | 14 | 2024 | 71 | 2.400 |
Why?
|
| Heart Failure | 11 | 2025 | 948 | 2.310 |
Why?
|
| Stroke Volume | 9 | 2024 | 339 | 2.020 |
Why?
|
| Cardiotoxicity | 9 | 2025 | 17 | 1.940 |
Why?
|
| Coronary Artery Disease | 4 | 2025 | 322 | 1.890 |
Why?
|
| Water Pollutants, Chemical | 2 | 2025 | 42 | 1.760 |
Why?
|
| Immunotherapy | 4 | 2025 | 265 | 1.750 |
Why?
|
| Cardiomyopathies | 5 | 2024 | 136 | 1.640 |
Why?
|
| Hypoglycemic Agents | 6 | 2026 | 225 | 1.570 |
Why?
|
| Antineoplastic Agents | 6 | 2023 | 639 | 1.420 |
Why?
|
| Atrial Fibrillation | 6 | 2024 | 869 | 1.410 |
Why?
|
| Stroke | 4 | 2025 | 1206 | 1.380 |
Why?
|
| Percutaneous Coronary Intervention | 5 | 2024 | 223 | 1.260 |
Why?
|
| Humans | 94 | 2026 | 64869 | 1.260 |
Why?
|
| Intracranial Hemorrhages | 2 | 2021 | 69 | 1.150 |
Why?
|
| Diabetic Retinopathy | 2 | 2026 | 60 | 1.070 |
Why?
|
| Environmental Exposure | 3 | 2025 | 226 | 1.020 |
Why?
|
| Ritonavir | 3 | 2023 | 18 | 1.020 |
Why?
|
| Climate Change | 3 | 2025 | 26 | 1.020 |
Why?
|
| Heart Diseases | 4 | 2025 | 219 | 1.010 |
Why?
|
| Medical Oncology | 8 | 2025 | 67 | 0.990 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2024 | 100 | 0.970 |
Why?
|
| Cardiology | 5 | 2024 | 168 | 0.950 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2025 | 6 | 0.920 |
Why?
|
| Seawater | 1 | 2025 | 10 | 0.920 |
Why?
|
| Aged | 35 | 2026 | 14867 | 0.920 |
Why?
|
| Catheter Ablation | 2 | 2024 | 154 | 0.870 |
Why?
|
| Middle Aged | 32 | 2026 | 18161 | 0.860 |
Why?
|
| Risk Factors | 24 | 2026 | 5401 | 0.850 |
Why?
|
| Perioperative Care | 1 | 2025 | 86 | 0.830 |
Why?
|
| Retrospective Studies | 21 | 2026 | 6826 | 0.810 |
Why?
|
| Nervous System Diseases | 1 | 2025 | 107 | 0.810 |
Why?
|
| Female | 41 | 2026 | 33895 | 0.780 |
Why?
|
| Hypertension | 3 | 2025 | 610 | 0.760 |
Why?
|
| Cardiovascular Agents | 2 | 2022 | 106 | 0.740 |
Why?
|
| Overweight | 1 | 2024 | 256 | 0.730 |
Why?
|
| Male | 40 | 2026 | 30935 | 0.720 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 214 | 0.690 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2026 | 171 | 0.680 |
Why?
|
| Septal Occluder Device | 1 | 2021 | 11 | 0.680 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2023 | 269 | 0.670 |
Why?
|
| Cross Infection | 2 | 2020 | 165 | 0.660 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 54 | 0.640 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 42 | 0.640 |
Why?
|
| Cardiovascular System | 1 | 2020 | 40 | 0.630 |
Why?
|
| Venous Thrombosis | 2 | 2018 | 112 | 0.630 |
Why?
|
| Atrial Appendage | 1 | 2021 | 41 | 0.630 |
Why?
|
| Risk Assessment | 11 | 2025 | 2090 | 0.630 |
Why?
|
| Drug-Eluting Stents | 2 | 2017 | 68 | 0.630 |
Why?
|
| Obesity | 2 | 2025 | 1262 | 0.610 |
Why?
|
| Heart Function Tests | 1 | 2018 | 16 | 0.580 |
Why?
|
| Heating | 1 | 2018 | 6 | 0.580 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2018 | 7 | 0.580 |
Why?
|
| Air Microbiology | 1 | 2018 | 11 | 0.580 |
Why?
|
| Medical Overuse | 1 | 2018 | 15 | 0.580 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 172 | 0.570 |
Why?
|
| Equipment Contamination | 1 | 2018 | 34 | 0.570 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2018 | 16 | 0.570 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 431 | 0.560 |
Why?
|
| Registries | 8 | 2025 | 901 | 0.560 |
Why?
|
| United States | 18 | 2026 | 8062 | 0.560 |
Why?
|
| Iliac Vein | 1 | 2018 | 10 | 0.550 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.550 |
Why?
|
| Sarcoidosis | 1 | 2018 | 34 | 0.550 |
Why?
|
| Kidney Diseases | 3 | 2025 | 177 | 0.550 |
Why?
|
| Pyrazoles | 1 | 2018 | 88 | 0.540 |
Why?
|
| Adult | 20 | 2025 | 17277 | 0.540 |
Why?
|
| Pyrimidines | 1 | 2018 | 146 | 0.530 |
Why?
|
| Pharmacovigilance | 4 | 2024 | 15 | 0.520 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2017 | 13 | 0.520 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 207 | 0.510 |
Why?
|
| Vascular Access Devices | 1 | 2017 | 15 | 0.510 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.510 |
Why?
|
| Stents | 2 | 2017 | 494 | 0.490 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 4 | 2024 | 48 | 0.490 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 126 | 0.480 |
Why?
|
| Treatment Outcome | 11 | 2025 | 5769 | 0.470 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 174 | 0.470 |
Why?
|
| Thrombolytic Therapy | 1 | 2017 | 195 | 0.460 |
Why?
|
| Aged, 80 and over | 13 | 2025 | 5571 | 0.440 |
Why?
|
| Quality of Life | 1 | 2022 | 1256 | 0.440 |
Why?
|
| Ventricular Function, Left | 5 | 2024 | 278 | 0.430 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 196 | 0.430 |
Why?
|
| Prevalence | 4 | 2025 | 1437 | 0.420 |
Why?
|
| Endovascular Procedures | 2 | 2017 | 628 | 0.400 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2025 | 148 | 0.390 |
Why?
|
| Cardiologists | 2 | 2023 | 28 | 0.390 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 366 | 0.390 |
Why?
|
| Air Pollution | 2 | 2023 | 40 | 0.380 |
Why?
|
| Electrocardiography | 4 | 2021 | 550 | 0.380 |
Why?
|
| United States Food and Drug Administration | 2 | 2024 | 90 | 0.380 |
Why?
|
| Pandemics | 5 | 2023 | 670 | 0.350 |
Why?
|
| Angioedema | 2 | 2021 | 10 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2026 | 797 | 0.320 |
Why?
|
| Myocardial Infarction | 3 | 2023 | 916 | 0.310 |
Why?
|
| Acute Coronary Syndrome | 2 | 2023 | 252 | 0.310 |
Why?
|
| Cardiac Catheterization | 3 | 2026 | 292 | 0.300 |
Why?
|
| Incidence | 6 | 2026 | 1412 | 0.300 |
Why?
|
| Observational Studies as Topic | 3 | 2026 | 66 | 0.300 |
Why?
|
| Young Adult | 8 | 2025 | 4784 | 0.300 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 1216 | 0.290 |
Why?
|
| Databases, Factual | 4 | 2025 | 885 | 0.290 |
Why?
|
| Anthracyclines | 3 | 2023 | 11 | 0.280 |
Why?
|
| Heart Rate | 2 | 2021 | 328 | 0.280 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 48 | 0.270 |
Why?
|
| Hospitalization | 6 | 2024 | 1386 | 0.270 |
Why?
|
| Adolescent | 8 | 2025 | 6298 | 0.260 |
Why?
|
| Diabetic Angiopathies | 1 | 2026 | 29 | 0.240 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2026 | 23 | 0.240 |
Why?
|
| Tricuspid Valve | 1 | 2026 | 28 | 0.240 |
Why?
|
| Cross-Sectional Studies | 4 | 2025 | 2696 | 0.230 |
Why?
|
| Echocardiography | 2 | 2020 | 511 | 0.220 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2026 | 69 | 0.220 |
Why?
|
| Mobility Limitation | 1 | 2025 | 49 | 0.220 |
Why?
|
| Heart-Assist Devices | 2 | 2025 | 158 | 0.220 |
Why?
|
| Hodgkin Disease | 1 | 2025 | 54 | 0.220 |
Why?
|
| Predictive Value of Tests | 4 | 2022 | 1104 | 0.220 |
Why?
|
| Social Determinants of Health | 2 | 2024 | 149 | 0.220 |
Why?
|
| Follow-Up Studies | 3 | 2026 | 2483 | 0.220 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2024 | 142 | 0.220 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2025 | 66 | 0.210 |
Why?
|
| Lymphoma | 1 | 2025 | 101 | 0.210 |
Why?
|
| Alopecia | 1 | 2024 | 28 | 0.210 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2026 | 111 | 0.210 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2024 | 3 | 0.210 |
Why?
|
| Bayes Theorem | 1 | 2024 | 125 | 0.210 |
Why?
|
| Shock, Cardiogenic | 1 | 2025 | 108 | 0.200 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2023 | 6 | 0.200 |
Why?
|
| Metabolic Syndrome | 1 | 2025 | 146 | 0.200 |
Why?
|
| Nutrition Surveys | 1 | 2024 | 147 | 0.200 |
Why?
|
| Amyloidosis | 1 | 2024 | 68 | 0.200 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2023 | 37 | 0.200 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2025 | 95 | 0.200 |
Why?
|
| Propensity Score | 1 | 2024 | 189 | 0.190 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2023 | 20 | 0.190 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2023 | 100 | 0.190 |
Why?
|
| Suicide | 1 | 2024 | 145 | 0.190 |
Why?
|
| Heart Valve Diseases | 1 | 2023 | 93 | 0.180 |
Why?
|
| Drug Interactions | 1 | 2022 | 124 | 0.180 |
Why?
|
| Vinca Alkaloids | 1 | 2021 | 1 | 0.180 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2024 | 110 | 0.180 |
Why?
|
| Taxoids | 1 | 2021 | 25 | 0.180 |
Why?
|
| Air Pollutants | 1 | 2023 | 98 | 0.180 |
Why?
|
| Heart | 3 | 2021 | 297 | 0.180 |
Why?
|
| Hyperkalemia | 1 | 2021 | 20 | 0.170 |
Why?
|
| Angiotensin II | 1 | 2021 | 25 | 0.170 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 46 | 0.170 |
Why?
|
| Shock | 1 | 2021 | 33 | 0.170 |
Why?
|
| Giant Cells | 1 | 2021 | 16 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 462 | 0.170 |
Why?
|
| Medicare | 2 | 2023 | 615 | 0.170 |
Why?
|
| Aortic Valve Stenosis | 1 | 2024 | 190 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 372 | 0.170 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 295 | 0.170 |
Why?
|
| Hypotension | 1 | 2021 | 50 | 0.170 |
Why?
|
| Time Factors | 4 | 2025 | 3750 | 0.170 |
Why?
|
| Heart Conduction System | 1 | 2021 | 50 | 0.170 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 70 | 0.170 |
Why?
|
| Bundle-Branch Block | 1 | 2020 | 15 | 0.160 |
Why?
|
| Biopsy | 2 | 2021 | 454 | 0.160 |
Why?
|
| Action Potentials | 1 | 2021 | 113 | 0.160 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 131 | 0.160 |
Why?
|
| Rural Population | 1 | 2022 | 224 | 0.160 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2023 | 233 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2022 | 224 | 0.160 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 73 | 0.160 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 493 | 0.160 |
Why?
|
| Heart Arrest | 1 | 2022 | 175 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2025 | 704 | 0.150 |
Why?
|
| Atherosclerosis | 1 | 2021 | 159 | 0.150 |
Why?
|
| Asthma | 1 | 2023 | 476 | 0.150 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 142 | 0.140 |
Why?
|
| Dementia | 1 | 2022 | 272 | 0.140 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 988 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 181 | 0.140 |
Why?
|
| Physical Examination | 1 | 2018 | 110 | 0.140 |
Why?
|
| Adenine | 1 | 2018 | 49 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 2018 | 61 | 0.140 |
Why?
|
| Global Health | 1 | 2019 | 180 | 0.140 |
Why?
|
| Operating Rooms | 1 | 2018 | 59 | 0.140 |
Why?
|
| Piperidines | 1 | 2018 | 74 | 0.140 |
Why?
|
| Comorbidity | 2 | 2019 | 1112 | 0.140 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 98 | 0.130 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2024 | 794 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 105 | 0.130 |
Why?
|
| Anticoagulants | 2 | 2022 | 520 | 0.130 |
Why?
|
| Drug Combinations | 3 | 2023 | 166 | 0.130 |
Why?
|
| Hypothyroidism | 1 | 2017 | 43 | 0.130 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 24 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 461 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 703 | 0.130 |
Why?
|
| Attitude | 1 | 2017 | 101 | 0.130 |
Why?
|
| Prosthesis Design | 1 | 2017 | 218 | 0.130 |
Why?
|
| Fatal Outcome | 1 | 2017 | 123 | 0.130 |
Why?
|
| Device Removal | 1 | 2017 | 64 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 460 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 168 | 0.120 |
Why?
|
| Influenza, Human | 1 | 2019 | 203 | 0.120 |
Why?
|
| Lyme Disease | 1 | 2017 | 123 | 0.120 |
Why?
|
| Equipment Design | 1 | 2017 | 358 | 0.120 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 140 | 0.120 |
Why?
|
| Ultrasonography, Interventional | 1 | 2017 | 119 | 0.120 |
Why?
|
| Lower Extremity | 1 | 2017 | 159 | 0.110 |
Why?
|
| Patient Selection | 1 | 2017 | 480 | 0.110 |
Why?
|
| Length of Stay | 3 | 2023 | 826 | 0.110 |
Why?
|
| Curriculum | 1 | 2018 | 607 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 803 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 2236 | 0.090 |
Why?
|
| Aminobutyrates | 2 | 2021 | 9 | 0.080 |
Why?
|
| Valsartan | 2 | 2021 | 12 | 0.080 |
Why?
|
| Trastuzumab | 2 | 2021 | 20 | 0.080 |
Why?
|
| Tetrazoles | 2 | 2021 | 22 | 0.080 |
Why?
|
| Biphenyl Compounds | 2 | 2021 | 30 | 0.080 |
Why?
|
| Troponin T | 2 | 2022 | 24 | 0.080 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2021 | 63 | 0.080 |
Why?
|
| Inpatients | 2 | 2023 | 314 | 0.080 |
Why?
|
| Hospitals | 2 | 2022 | 385 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2022 | 874 | 0.070 |
Why?
|
| Algorithms | 2 | 2024 | 1040 | 0.070 |
Why?
|
| Liraglutide | 1 | 2026 | 8 | 0.060 |
Why?
|
| Glucagon-Like Peptides | 1 | 2026 | 8 | 0.060 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2026 | 30 | 0.060 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2026 | 48 | 0.060 |
Why?
|
| Vincristine | 1 | 2025 | 26 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1134 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2024 | 3303 | 0.060 |
Why?
|
| Hematology | 1 | 2025 | 12 | 0.060 |
Why?
|
| Dyslipidemias | 1 | 2025 | 39 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2025 | 84 | 0.060 |
Why?
|
| Prednisone | 1 | 2025 | 83 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2025 | 98 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2024 | 32 | 0.050 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 14 | 0.050 |
Why?
|
| Canagliflozin | 1 | 2024 | 6 | 0.050 |
Why?
|
| Pericarditis | 1 | 2024 | 10 | 0.050 |
Why?
|
| Glucosides | 1 | 2024 | 15 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2026 | 502 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2026 | 733 | 0.050 |
Why?
|
| Lactams | 1 | 2023 | 23 | 0.050 |
Why?
|
| Natural Language Processing | 1 | 2024 | 52 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2024 | 78 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2025 | 319 | 0.050 |
Why?
|
| Proline | 1 | 2023 | 48 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2025 | 248 | 0.050 |
Why?
|
| Benzhydryl Compounds | 1 | 2024 | 61 | 0.050 |
Why?
|
| Child | 2 | 2024 | 4609 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2026 | 497 | 0.050 |
Why?
|
| Leucine | 1 | 2023 | 67 | 0.050 |
Why?
|
| Nitriles | 1 | 2023 | 84 | 0.050 |
Why?
|
| Cause of Death | 1 | 2024 | 222 | 0.050 |
Why?
|
| Environmental Pollution | 1 | 2023 | 14 | 0.050 |
Why?
|
| Benzoxazoles | 1 | 2023 | 7 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2025 | 289 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 155 | 0.050 |
Why?
|
| Prealbumin | 1 | 2023 | 21 | 0.050 |
Why?
|
| Sex Factors | 1 | 2026 | 987 | 0.050 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2023 | 13 | 0.050 |
Why?
|
| Mortality | 1 | 2024 | 160 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2023 | 43 | 0.050 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2023 | 15 | 0.050 |
Why?
|
| Aortic Valve | 1 | 2024 | 181 | 0.050 |
Why?
|
| Mitral Valve | 1 | 2023 | 126 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2024 | 276 | 0.050 |
Why?
|
| Machine Learning | 1 | 2024 | 192 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 400 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2023 | 211 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 797 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2023 | 292 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2022 | 105 | 0.040 |
Why?
|
| Endocardium | 1 | 2021 | 14 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2021 | 27 | 0.040 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2021 | 23 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 161 | 0.040 |
Why?
|
| Troponin I | 1 | 2021 | 36 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 58 | 0.040 |
Why?
|
| Niacinamide | 1 | 2020 | 32 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2023 | 323 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2024 | 387 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 140 | 0.040 |
Why?
|
| Proteasome Inhibitors | 1 | 2020 | 32 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 314 | 0.040 |
Why?
|
| Phenotype | 1 | 2024 | 1232 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 62 | 0.040 |
Why?
|
| Gadolinium | 1 | 2020 | 110 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2021 | 180 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2020 | 191 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 277 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2020 | 116 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 209 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 198 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2023 | 445 | 0.040 |
Why?
|
| Survivorship | 1 | 2018 | 14 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 380 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 850 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2018 | 37 | 0.030 |
Why?
|
| Program Development | 1 | 2019 | 207 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 138 | 0.030 |
Why?
|
| Defibrillators, Implantable | 1 | 2021 | 273 | 0.030 |
Why?
|
| Contrast Media | 1 | 2020 | 428 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 1006 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2023 | 2609 | 0.030 |
Why?
|
| Exercise Test | 1 | 2018 | 256 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2756 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2019 | 490 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 436 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 2058 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2018 | 189 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2017 | 117 | 0.030 |
Why?
|
| Melanoma | 1 | 2020 | 332 | 0.030 |
Why?
|
| Vaccination | 1 | 2019 | 374 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1472 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 702 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 1655 | 0.020 |
Why?
|
| Animals | 1 | 2025 | 21382 | 0.020 |
Why?
|